Obafemi Awolowo University   Report issue

Academic/Hospital Phase 2 Phase 3
Founded: Ife Nigeria (1961)

Organization Overview

First Clinical Trial
2013
NCT01946256
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Adeniyi Olagunju | Department of Clinical Pharmacy and Pharmacy Administration, Obafemi Awolowo University, Ile Ife Nigeria | Obafemi Awolowo University | Obafemi Awolowo University Hospitals Complex, Ile-Ife, Nigeria | Obafemi Awolowo University Ile Ife | Obafemi Awolowo University, Ile Ife | Obafemi Awolowo University, Ile Ife. Nigeria | Obafemi Awolowo University, Nigeria | Obafemi Awolowo University Teaching Hospital | Obafemi Awolowo University Teaching Hospitals | Obafemi Awolowo University Teaching Hospitals Complex | Obafemi Awolowo University Teaching Hospitals Complex, Ile-Ife

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Chlamydia Infections (Phase 2)

Communicable Diseases (Phase 2)

Infections (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 6
  • # of Trial APIs: 11